Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 8:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 20,160 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety and Efficacy Clear all
Completed Phase 1 Interventional Results available

Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease

NCT01977781
View directory record Official record
Conditions
Ocular GVHD
Interventions
Tacrolimus, Methylprednisolone Sodium Succinate
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 5, 2026, 8:14 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Comparison of Two Modes of Photodynamic Therapy for the Treatment of Actinic Keratosis on the Upper Extremities

NCT05359419
View directory record Official record
Conditions
Skin Neoplasms
Interventions
aminolevulinic acid hydrochloride gel, 10%, aminolevulinic acid HCl topical solution, 20%
Combination Product
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
35 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 5, 2026, 8:14 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Efficacy and Safety of K-285 Compared With Menthol Gel for the Treatment of Delayed Onset Muscle Soreness (DOMS) in the Lower Extremity

NCT04484428
View directory record Official record
Conditions
Acute Pain
Interventions
K-285, Menthol
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 5, 2026, 8:14 AM EDT
Completed No phase listed Observational

Pharmacist-Driven Stress Ulcer Prophylaxis Minimization in the Intensive Care Unit

NCT06225167
View directory record Official record
Conditions
Stress Ulcer
Interventions
To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.
Behavioral
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 5, 2026, 8:14 AM EDT
Not yet recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

NCT07816367
View directory record Official record
Conditions
Migraine
Interventions
Elismetrep, Placebo
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
72
States / cities
Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 5, 2026, 8:14 AM EDT
Completed Phase 3 Interventional Results available

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT01749930
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
BOL-303259-X, Timolol
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 5, 2026, 8:14 AM EDT
Completed Phase 3 Interventional Results available

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

NCT04713592
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo for Risankizumab, Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
34
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 5, 2026, 8:14 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)

NCT04647253
View directory record Official record
Conditions
In-Stent Restenosis
Interventions
AGENT DCB, PTCA balloon catheter
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
40
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 5, 2026, 8:14 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

NCT00099853
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Vildagliptin, pioglitazone, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 5, 2026, 8:14 AM EDT
Completed Phase 3 Interventional

A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

NCT01192867
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO4917838, Antipshychotics (Standard of Care)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
27
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 5, 2026, 8:14 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

NCT05938036
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
ALT-100 mAb, ALT-100 (Placebo)
Drug
Lead sponsor
Aqualung Therapeutics Corp.
Industry
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 5, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection

NCT03361956
View directory record Official record
Conditions
Hepatitis B
Interventions
JNJ-56136379, Placebo, NA (ETV or TDF)
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
18 Years to 70 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Bakersfield, California • Orlando, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 5, 2026, 8:14 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

NCT06263231
View directory record Official record
Conditions
Sarcoma,Soft Tissue
Interventions
INT230-6, Eribulin, Trabectedin, Pazopanib
Drug
Lead sponsor
Intensity Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 5, 2026, 8:14 AM EDT
Completed Phase 3 Interventional Results available

Fesoterodine "add-on" Male Overactive Bladder Study

NCT00546637
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years and older · Male only
Enrollment
947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2011 · Synced Oct 5, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)

NCT04995081
View directory record Official record
Conditions
Parkinson Disease
Interventions
Biological/Vaccine: Allogeneic HB-adMSCs, Placebo
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
45 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 5, 2026, 8:14 AM EDT
Completed Phase 1 Interventional

STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency

NCT00263237
View directory record Official record
Conditions
Common Variable Immunodeficiency
Interventions
STA-5326
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 5, 2026, 8:14 AM EDT
Completed Phase 1Phase 2 Interventional

Delayed Infusion of DCreg in Living Donor Liver Transplantation

NCT04208919
View directory record Official record
Conditions
Living Donor Liver Transplantation
Interventions
Donor-derived DCreg
Biological
Lead sponsor
Angus W. Thomson PhD DSc
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 5, 2026, 8:14 AM EDT
Completed Phase 2 Interventional

Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

NCT03339128
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
26
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Corona, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 5, 2026, 8:14 AM EDT
Terminated Phase 2 Interventional Results available

Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen

NCT04839965
View directory record Official record
Conditions
COVID-19
Interventions
Ampion, Saline
Biological · Other
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 5, 2026, 8:14 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

NCT05926765
View directory record Official record
Conditions
Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Interventions
AAV2-hAQP1 Concentration 1, AAV2-hAQP1 Concentration 2, Placebo, AAV2-hAQP1 Concentration 3, AAV2-hAQP1 Concentration 4
Genetic · Other
Lead sponsor
MeiraGTx, LLC
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
18
States / cities
Gilbert, Arizona • Duarte, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 5, 2026, 8:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

NCT01365507
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Concord, California • Los Angeles, California • Montclair, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 5, 2026, 8:14 AM EDT
Completed Phase 4 Interventional Results available

An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)

NCT01338636
View directory record Official record
Conditions
Exercise-induced Pulmonary Arterial Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 5, 2026, 8:14 AM EDT
Not yet recruiting Phase 4 Interventional

Steroid Treatment for Severe Acute Respiratory Infection (STAR) Trial

NCT07199192
View directory record Official record
Conditions
Hypoxemia, Severe Acute Respiratory Syndrome
Interventions
Corticosteroid
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 5, 2026, 8:14 AM EDT
Completed Phase 3 Interventional

Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 1 Diabetes Mellitus.

NCT00424437
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Inhaled human insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
29
States / cities
Burlingame, California • Irvine, California • Newport Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2007 · Synced Oct 5, 2026, 8:14 AM EDT